【摘要】 食管癌是我国第五大致死性肿瘤，每年新发病例和死亡病例均约占全球的一半，其中食管鳞状细胞癌占90%以上，5a生存率为29.6%。随着放疗技术的进步和化疗方案的优化，同步放化疗在多项临床研究中取得突破，推动食管癌的整体治疗局面发生了根本性改变，国际、国内多个指南将新辅助同步放化疗加手术、根治性同步放化疗或新辅助放化疗后达临床完全缓解，后续密切随访+挽救性手术推荐为局部晚期食管癌的并列选择，为探索局部可切除食管癌患者“保器官”设想提供了理论依据和新的思路。为更好地指导食管癌同步放化疗全程管理，提升食管癌同步放化疗的科学性和规范性，中国抗癌协会感染性肿瘤专业委员会组织国内相关领域专家，经过多轮深入讨论和修改，系统性地梳理了国内外最新的指南和循证医学证据，并充分考虑我国临床实践的具体情况，形成本专家共识。更多还原

【Abstract】 Esophageal cancer is the fourth most lethal tumor in China, accounting for about half of the world’s new cases and deaths each year, of which esophageal squamous cell carcinoma accounts for more than 90%,with a 5-year survival rate of 29.6%. With the advancement of radiotherapy technology and optimization of chemotherapy regimen, concurrent chemoradiotherapy has made breakthrough progress which has pushed the overall treatment situation of esophageal cancer to a fundamental change. Several international guidelines recommend neoadjuvant concurrent chemoradiotherapy plus surgery or definitive concurrent chemoradiotherapy as a side-by-side choice for locally advanced esophageal cancer, which provides a theoretical basis for the “organ preservation” concept for patients with locally resectable esophageal cancer. It provides theoretical basis and new ideas for the concept of “organ preservation” for patients with locally resectable esophageal cancer. In order to better guide the whole processing management of concurrent chemoradiotherapy for esophageal cancer, the Infectious Cancer Committee, Chinese and Western Medicine Integrated Esophageal Cancer Committee and Esophageal Cancer Integrative Rehabilitation Committee of the China Anti-Cancer Association have organized domestic experts in related fields, and after several rounds of in-depth discussions and modifications, systematically sorted out the latest domestic and international guidelines and evidence-based medical evidence, and fully considered the specific conditions of clinical practice in China, to form the present expert consensus.更多还原